weight. The main objective is to conduct a pharmacoeconomic analysis to find out the cost effectiveness of Diethylpropion with diet and exercise. (DEPϩDaE), compared against Diet and Exercise (DaE) in Mexico. METHODS: The point of view of the study was the supplier of IMSS health services. The target population were men and women over 18 years with BMI Ն30 kg/m 2 . Outcome measures were the reduction of weight in kg and Quality Adjusted Life Years (QALYs). The direct costs in the treatment of obesity were assessed, treatment of adverse events and complications (Type 2 Diabetes Mellitus and cardiovascular disease). We used a Dynamic, Stochastic Discrete Model (DSD) and a univariate and probabilistic sensitivity analysis was performed. All the quantities expresed in Mexican pesos (MXP) RESULTS: DEPϩDaE presented a lower cost and improved the utility and effectiveness when compared DaE. Incremental cost was $18,361MXP in males and $16,285MXP in women. Incremental effectiveness and utility was 4.19 kg and 0.10 QALYs in men and 3.77 kg and 0.08 QALYs in women. ICER pointed the absolute dominance for DEPϩDaE. Estimated savings per 100 patients in the IMSS can be $1,697,027MXP if complemented by a 100% change health habits using DEPϩDaE. CONCLUSIONS: The combination of DEPϩDaE provides a cost effective improvement to the treatment of patients with a risk profile for obesity.
OBJECTIVES: Recent randomized trials (RCT) have suggested erythropoiesis stimulating agents (ESA) reduce mortality in critically ill trauma patients; however ESA are costly. We sought to determine cost-effectiveness of ESA in this patient population. METHODS: A decision analytic model was constructed to compare the use of ESA to standard care in trauma patients admitted to an intensive care setting. Base case costs and benefits at one year were estimated using mortality estimates from available RCTs. One way and probabilistic sensitivity analyses were conducted for comparison of the base case scenario with 10 and 25 year time horizons in Markov models. RESULTS: ESA use was associated with a cost per QALY gained of $74,500 to $81,748 compared with standard care at one year. One-way sensitivity analyses indicated results were sensitive to changes in mortality risk, risk of thrombosis, relative risk of mortality, relative risk of thrombosis, and quality of life estimates. Cost effectiveness acceptability curves generated from probabilistic sensitivity analysis indicated that the probability ESA would be considered attractive ranged from 35% to 80% over the range of WTP of $60,000 to $120,000. Consideration of longer time horizons reduced the cost per QALY gained to $9,338 Ϫ $5,957. CONCLUSIONS: While the cost per QALY gained with ESA use falls into the range of currently accepted healthcare technologies funded in Canada, significant uncertainty exits, particularly long-term survival benefit with ESA use. Further research into the efficacy and safety of ESA use in critically ill trauma patients is required prior to widespread use. 
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COST-UTILITY ANALYSES OF DIFFERENT ERYTROPOIETINS IN ANEMIC PATIENTS ON DIALYSIS IN RUSSIA
OBJECTIVES:
To examine cost-utility of different erythropoietins (epoetin alfa and epoetin beta) in Russian anemic patients on dialysis. METHODS: Health survey of patients in dialysis departments of 23 regions. About 1400 questionnaires were distributed in May -June 2010. Health-related quality of life was assessed with self-administrated validated version of Russian version of Euroqol-5D questionnaire. Inclusion criteria were age older than 18 years, terminal stage of chronic renal failure and treatment with dialysis more then 4 months. All patients have been divided on four subgroups depending on the name of received erythropoietin. Direct cost contains of cost of erythropoietin, administration cost, cost of iron supplemention was calculated. RESULTS: 1395 completed questionnaires were received by September, 2010. Detailed analysis of antianemic therapy has shown that 85% patients received erytropoetins. There were four the most used drugs: Recormon (epoetin beta) (42%), Eralfon (epoetin alfa) (18%), Epocrinum (epoetin alfa) (16%), Eprex (epoetin alfa) (9%). Groups were not differ according to the level of hemoglobin. Average HRQL, assessed with VAS, was not differ significantly between 4 groups: 0.62 for Eralfon, 0.59 for Recormon, 0.585 for Eprex, 0.56 for Epocrinum. Per year cost of treatment with Eprex was 5 382 USD, with Eralfon -4 463 USD, with Recormon -4 204 USD, with Epocrinum -1 652 USD. Lifelong costs of treatment with Eprex was 50 017 USD, with Eralfon -49 098 USD, with Recormon -48 785 USD, with Epocrinum -46 596 USD. The cost per QALY was 85 499 USD per QALY for Eprex, 83 505 USD per QALY for Epocrinum, 82 547 USD per QALY for Recormon and 75 596 USD per QALY for Eralfon. CONCLUSIONS: Present costutility analyses revealed that in Russian anemic patients on dialysis the most cost-effective strategy of antianemic therapy among 4 common erythropoietins was Eralfon with 75 596 USD per QALY. OBJECTIVES: Inflammatory Bowel Disease (IBD) is an immune-mediated inflammatory disorder which includes Crohn's disease and ulcerative colitis. The relationship between out-of-pocket (OOP) healthcare costs with productivity is not well known in IBD. This study explores the relationship of OOP healthcare costs on productivity. METHODS: Participants self-identified with IBD and aged Ն18 completed an internet-based cross-sectional survey in 1Q2009. Self-reported productivity loss including absenteeism, presenteeism, overall work impairment and activity impairment expressed as impairment percentages, were measured by the Work Productivity and Activity Impairment questionnaire. Participants were asked about IBD-related and overall monthly OOP healthcare costs. Negative binomial regression models were developed to adjust for age, gender, ethnicity, income, education, and marital status. RESULTS: 534 participated, 67% were female, 55% were employed, and 13% were on short-and long-term disability. More than half (53%) reported annual household incomes between $50-100K, 40% were college educated. Overall OOP costs were: $0-$50 for 52.6%, $51-$100 for 18.2%, $101-$200 for 15.5%, and Ͼ $200 for 13.7%. Among employed, rates of absenteeism, presenteeism, and overall work impairment were 9.97%, 16.3% and 20.0%, respectively. 43.2% reported impairment in daily activities. Significantly greater productivity loss (presenteeism, b ϭ 2.79, p ϭ 0.0004) and overall work impairment (b ϭ 2.78, p ϭ 0.0006) were observed among patients with overall OOP costs Ͼ$200, as compared to those with OOP costs between $0-50 after adjusting for patient demographics. CONCLUSIONS: Higher monthly OOP costs were associated with higher work impairment and lower productivity. Shifting healthcare costs to employees maybe associated with productivity loss. Further research is needed to determine longerterm impact of OOP healthcare costs on work productivity.
PSY25 RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
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IMPACT OF HYPONATREMIA ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS
Deitelzweig S 1 , Amin A 2 , Lin J 3 , Belk K 4 , Baumer D 4 , Lowe T 5 1 Ochsner Health System, New Orleans, LA, USA, 2 University of California, Irvine, Irvine, CA, USA, 3 Novosys Health, Flemington, NJ, USA, 4 Premier, Inc., Charlotte, NC, USA, 5 Premier Healthcare Alliance, Charlotte, NC, USA OBJECTIVES: Hyponatremia (HN) is the leading electrolyte abnormality among hospitalized patients. In the absence of symptoms, HN is often overlooked as a condition that warrants aggressive intervention. Though HN is common, little is known regarding the influence of HN on patient outcomes and healthcare resource utilization. This study assessed the impact of HN on inpatient total and intensive care unit (ICU) cost, total and ICU length of stay (LOS), likelihood of ICU admission, and 30-, 90-, and 180-day readmission. METHODS: Premier's Perspective® database was utilized to construct a stratified sample of hospital inpatients discharged between January 1, 2007 and June 30, 2009. HN patients were identified using primary or secondary diagnosis of HN (nϭ558,815) and were matched to a non-HN control group (nϭ558,815) using exact matching of age, gender, provider region, and 3M™ APR-DRG assignment. Matching was further refined using propensity scores based on additional patient and hospital characteristics and patient comorbidities. Cost was analyzed using a multivariate general linear regression model with gamma distribution and log-link, LOS with negative binomial distribution and log-link, and ICU admission and hospital readmission with multivariate logistic regression. RESULTS: In contrast to non-HN patients, patients with HN had significantly higher total inpatient cost (9.49%, CIϭ8.99-10.00; pϽ.0001), ICU cost (9.12%; CIϭ8.04-10.23; pϽ.0001), total LOS (12.24%, CIϭ11.85-12.64; pϽ.0001), and ICU LOS (11.06%, CIϭ9.60-12.54; pϽ.0001). HN patients were significantly more likely to be A63 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
